Connetics plans new trial for Extina

Seven months after receiving a not approvable letter from the FDA for Extina -- an experimental skin treatment -- Connetics says it will begin a late-stage trial in the third quarter to prove it works. Extina was developed for an inflammatory skin disease called seborrhic dermatitis. Connetics says its new schedule will put it on track to file another NDA on the treatment in the second half of 2006.

- read this story from Forbes for more

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.